mecasermin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
insulin-like growth factors 5009 68562-41-4

Description:

MoleculeDescription

Synonyms:

  • mecasermin recombinant
  • mecasermin
  • increlex
  • somatomedin C
  • Somatomedin-C
  • IGF1
  • insulin-like growth factor 1
Recombinant form of endogenous Insulin-like Growth Factor 1 exhibiting mitogenic activity. Clinical Use: Diabetes Mellitus and Amyotrophic Lateral Sclerosis.
  • Molecular weight: 7648.71
  • Formula: C331H512N94O101S7
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 3126.93
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 8, 2007 EMA
Aug. 30, 2005 FDA IPSEN INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 58.76 41.45 19 282 58994 53289771
Tonsillar hypertrophy 43.93 41.45 7 294 863 53347902

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tonsillar hypertrophy 120.19 49.62 19 646 602 32512259
Product dose omission issue 60.76 49.62 33 632 102542 32410319
Adenoidal hypertrophy 56.77 49.62 8 657 112 32512749
Hypoglycaemia 51.23 49.62 24 641 54358 32458503

Pharmacologic Action:

SourceCodeDescription
ATC H01AC03 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
Somatropin and somatropin agonists
MeSH PA D006133 Growth Substances

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Laron-type isolated somatotropin defect indication 38196001 DOID:9521

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Insulin-like growth factor 1 receptor Kinase AGONIST IC50 8.31 SCIENTIFIC LITERATURE DRUG LABEL
Insulin receptor Kinase IC50 5.85 SCIENTIFIC LITERATURE

External reference:

IDSource
D03297 KEGG_DRUG
4024932 VUID
N0000023113 NUI
4024932 VANDF
CHEBI:80343 CHEBI
CHEMBL1201716 ChEMBL_ID
C000604197 MESH_SUPPLEMENTAL_RECORD_UI
4971 IUPHAR_LIGAND_ID
6372 INN_ID
DB01277 DRUGBANK_ID
7GR9I2683O UNII
274403 RXNORM
20506 MMSL
71163 MMSL
d05636 MMSL
011016 NDDF
418157000 SNOMEDCT_US
418845006 SNOMEDCT_US
5699003 SNOMEDCT_US
C0904505 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Increlex HUMAN PRESCRIPTION DRUG LABEL 1 15054-1040 INJECTION, SOLUTION 40 mg SUBCUTANEOUS BLA 30 sections
Cosmeceutical Mask Pack HUMAN OTC DRUG LABEL 6 60709-102 PATCH 0.04 mg TOPICAL unapproved drug other 9 sections
Dermaheal Cosmeceutical Mask Pack Plus HUMAN OTC DRUG LABEL 6 60709-105 PATCH 0.04 mg TOPICAL unapproved drug other 9 sections